Immunome
Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates, radioligand therapies and a gamma secretase inhibitor. It aims to improve outcomes for cancer patients by advancing treatments for significant unmet medical needs.
Facts
- HQ
- Bothell, Washington, US
- Sectors
- Biotechnology Research
- Employees
- 283
- Founders
- Clay Siegall
Is this your organization? Claim it
Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics
Clay Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food andDrug Administration (FDA) in 2011. Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997…
People
-
Clay Siegall Executive, President and CEO
Online
Questions about Immunome
What is Immunome?
immunome.com
Who are the people behind Immunome?
Seattle Flow lists Clay Siegall (Executive, President and CEO) at Immunome.
Where is Immunome based?
Immunome is headquartered in Bothell, Washington, US.
How many people work at Immunome?
Immunome has 283 employees.